Add Row
Add Element
cropper
update
National Cannabis Newswire
update
Add Element
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
August 12.2025
2 Minutes Read

Kentucky Governor Urges Trump: Stop Blocking Cannabis Rescheduling Efforts

Cannabis plants with American flag backdrop, symbolizing rescheduling.

Kentucky’s Call for Cannabis Reform: Gov. Beshear Speaks Out

Kentucky Governor Andy Beshear has taken a bold step by directly appealing to President Trump, urging him to halt efforts that threaten the rescheduling of cannabis from its current Schedule I status. This crucial move highlights the growing urge within various sectors, particularly in health and wellness, for the recognition and reclassification of cannabis to Schedule III, enabling broader access and medical research opportunities.

The Politics of Cannabis Rescheduling

In his letter, Beshear targeted specific language in the ongoing Fiscal Year 2026 appropriations bill aimed at preventing the Department of Justice and the Drug Enforcement Administration from allocating funds towards the reclassification of marijuana under the Controlled Substances Act. He pushed back against the politicization of cannabis reform, labeling the current legislative actions as “not common-sense law.” Beshear’s critique underscores his commitment to ensuring that drug classifications are informed by scientific evidence rather than political maneuvering.

Impact on Public Health & Safety

The governor is not alone in his frustration; many advocacy groups and healthcare professionals echo his stance, arguing that keeping cannabis in Schedule I stifles vital medical research and access for patients in need. By advocating for a reclassification, Beshear emphasized the relief and accessibility it would bring to patients relying on medical marijuana as part of their treatment plans. His administration has already laid out groundwork to roll out medical cannabis programs in Kentucky by early 2025, highlighting the pressing need for appropriate regulatory compliance and patient protections.

A Patient-Centric Approach to Legislation

Beshear's remarks also reflect a broader cultural shift toward understanding cannabis as an essential resource for patient care rather than a recreational commodity. The existing stigma around marijuana continues to diminish as studies increasingly demonstrate its therapeutic benefits. Many cultivation experts believe that accessibility to medical marijuana could significantly shift health outcomes for patients suffering from chronic pain, anxiety, and various other health issues.

Future Predictions for Cannabis Access in Kentucky

As the state looks to implement its medical marijuana program, industry experts foresee a substantial transformation in how cannabis is perceived within the community. With safe access on the horizon, dispensaries might witness a surge in patients seeking alternative therapies, thereby fostering a more informed public discourse regarding cannabis culture in Kentucky. Education will be key in helping consumers navigate this new landscape, ensuring they are well-informed about the benefits and potential risks associated with medical cannabis.

Call to Action: Advocate Change for a Healthier Future

As cannabis reform gains traction in Kentucky, it is vital for individuals to engage with this evolving narrative. Supporting local advocacy groups, participating in community discussions, and voicing your thoughts can amplify the movement toward a more compassionate and science-driven approach to cannabis legislation. We all have a role to play in shaping a future that prioritizes health, wellness, and informed access to cannabis. Join the conversation and make your voice heard!

culture

61 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

Melt-to-Make Patented Gummy Base Technology Supports Scalable Cannabis Edibles Manufacturing 

FOR IMMEDIATE RELEASE Cannabis / Nutraceuticals / Manufacturing / Patent / Gummies / Growth / Scaling “Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president at Melt-to-Make. NORTHAMPTON, Mass. — February 20, 2026 — As the global cannabis edibles market continues to expand, manufacturers are facing growing pressure to deliver compliant, consistent, and scalable products. According to Fortune Business Insights, the cannabis edibles market is projected to exceed $55 billion by 2034, reflecting sustained double-digit compound annual growth.The expanding market is increasing demand for manufacturing systems that reduce formulation variability while improving production efficiency. In response, many producers are adopting standardized formulation platforms to support reliable output across product lines, facilities, and geographic markets. Melt-to-Make has introduced a patented gelatin and pectin gummy base technology designed to address persistent bottlenecks in large-batch edible production. The company’s shelf-stable semi-finished gummy base can be heated and infused with active ingredients before molding, helping manufacturers simplify workflows while improving repeatability.By standardizing the gummy base, the Melt-to-Make system reduces common manufacturing challenges associated with traditional confectionery production, including inconsistent texture, lengthy research and development cycles, and batch failures during scale-up.“Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president of product development and research at Melt-to-Make. “When the formulation system itself is consistent and repeatable, manufacturers can concentrate on dosing precision and operational efficiency rather than troubleshooting structure and texture.” Traditional gummy production often requires specialized confectionery equipment and advanced formulation expertise, particularly when working with pectin in vegan and heat-stable applications. Melt-to-Make’s semi-finished gummy base is designed to integrate into existing production workflows, giving manufacturers a more standardized substrate for predictable results.As regulated cannabis markets in the United States and Europe continue implementing stricter quality control and labeling standards, consistency in edible production is becoming increasingly important for both regulatory compliance and long-term brand reliability.Standardized ingredient systems are emerging as a practical solution for achieving repeatable performance in expanding markets. Melt-to-Make currently serves clients in more than 15 countries and provides technical documentation, formulation tools, and production support for manufacturers implementing the technology.To learn more, visit www.melt-to-make.com. About Melt-to-Make™ Founded in 2018 in Northampton, Massachusetts, by Sarah McLaughlin, Jake Goodyear, and Tim Van Epps, Melt-to-Make™ specializes in innovative gummy base systems designed to simplify large-batch gummy manufacturing. By offering professionally formulated gelatin and pectin bases that are approximately 90% complete, the company helps manufacturers produce gummies faster, more efficiently, and with greater consistency.Melt-to-Make™ is committed to using all-natural ingredients and colors while supporting a wide range of consumer preferences, including vegan, gluten-free, and non-GMO options. The company serves more than 1,000 B2B customers across the United States and in 15 countries, offering comprehensive support that includes equipment lists, training videos, custom formulations, and on-site technical assistance.For more information, visit www.melt-to-make.com or call 1-800-241-0341.Media ContactProven Media Kim Prince Phone: 480-221-7995 Email: kim@provenmedia.com

The Green Wave: Medical Cannabis Takes Root in 40 States

Update Understanding the Shift Towards Medical Cannabis A recent report from the National Conference of State Legislatures (NCSL) establishes that as of June 2025, a remarkable 40 states, three territories, and Washington, D.C., now permit the medical use of cannabis. This represents a significant shift within U.S. policy, highlighting the changing landscape of healthcare driven by patient needs and scientific findings. For cultivation experts, the implications of this green wave are profound, offering new opportunities to understand and engage with a diverse market. The Drivers Behind Cannabis Legalization Why has the acceptance of medical cannabis surged? Three interconnected factors play a crucial role: Patient Advocacy: Real-life testimonials from patients who have found relief from ailments such as chronic pain and anxiety have been central to this movement. Personal stories resonate widely, creating a groundswell of support amongst the general public. Scientific Research: Despite the challenges that federal restrictions place on cannabis research, the growing body of evidence supporting the therapeutic benefits of cannabinoids like THC and CBD is undeniable. Cultivators must stay informed about these studies to optimize their practices for various medical applications. Shifting Public Opinion: Understanding cannabis as a legitimate medical treatment rather than a mere recreational drug has become increasingly prevalent. This shift opens avenues for more robust education around its usage across various conditions, influencing not just patients but also healthcare practices. Diversifying Cannabis Products Today's cannabis market is diverse, moving beyond traditional smoked products to include a wide range of formulations catering to various consumer needs. For cultivation experts, this diversification presents both challenges and opportunities: Edibles: From gummies to chocolates, edibles offer smoke-free consumption and are growing in popularity among medical users seeking discretion. Tinctures and Oils: These products allow for precise dosing, appealing to patients who prefer measurement over guesswork. Topicals: Creams and balms are ideal for localized relief, ensuring that users can target specific areas without psychoactive effects. Vaporization: Known for quick onset, vaping remains one of the most user-friendly methods for medical cannabis consumption. Pills: The move towards pill form standardizes doses and effects, providing a familiar method to more users. The Future of Cannabis Legislation While states lead the charge in cannabis legalization, a significant paradox remains: cannabis is still illegal at the federal level, classified as a Schedule I substance. This inconsistency impacts not only consumer access but also research and market operations. Cultivation experts must navigate this unique legal environment and advocate for sensible reforms that reflect the realities of the marketplace. The trend hints at possible federal reforms on the horizon, which could dramatically alter the industry landscape. Conclusion: Embracing the Green Wave As the medical cannabis landscape evolves, it presents a dynamic environment for cultivation experts and consumers alike. The focus on patient needs, coupled with scientific advocacy, suggests a continued push toward integration within healthcare systems. The growing understanding of cannabis not only as a trend but as a legitimate aspect of health can no longer be ignored, driving cultivation experts to adapt and prepare for an industry that values quality, research, and patient advocacy.

Cannabis Businesses Face Long Road Ahead with 280E Tax Relief Concerns

Update The Ongoing Burden of 280E on Cannabis BusinessesThe cannabis industry is celebrating an important milestone with the potential rescheduling of cannabis from a Schedule I to a Schedule III substance. Yet, despite this significant change in federal perception, cannabis businesses should remain cautious about potential tax relief from the burdensome 280E tax code. It’s easy to get caught up in the excitement, but tax experts advise patience, indicating that immediate relief might not arrive just yet.Understanding the 280E Tax CodeSection 280E of the Internal Revenue Code is a frustrating reality for many cannabis businesses. It prohibits them from deducting business expenses related to the trafficking of controlled substances listed in Schedules I and II, including cannabis. This means that, unlike traditional retail businesses that can deduct the costs of rent, utilities, and salaries, cannabis businesses are taxed on their gross income. This leads to effective tax rates that can soar above 50%, placing an unfair financial burden on a burgeoning industry.What Could Change with Rescheduling?The proposed shift to Schedule III could signal a significant change, suggesting that the stringent restrictions tied to 280E might start to loosen. Schedule III substances are recognized for having medical uses and a lower potential for abuse. If cannabis were to move from Schedule I, theoretically 280E's application should weaken. However, the timeline for this process is murky and extends beyond mere rescheduling.Adapting Until the ChangeFor now, cannabis businesses must adapt to the existing framework. Experts recommend exploring different strategies to mitigate the overwhelming tax burden imposed by 280E. Options like implementing Employee Stock Ownership Plans (ESOPs) can effectively remove some income from taxable streams, allowing businesses to navigate the tax landscape more effectively. Alternatively, Section 471(c) provides pathways for certain small cannabis businesses to adjust their inventory accounting, enabling them to include otherwise disqualified costs in their Cost of Goods Sold (COGS).The Road Ahead: Why Patience is KeyDespite the positive outlook, cannabis businesses need to prepare for continued complications surrounding their tax obligations. While the eventual rescheduling heralds the potential for relief, it might take years before those changes impact tax filings effectively. This is especially true if the IRS requires time to implement adjustments and for tax guidance to be updated accordingly.Final Thoughts: A Balanced Perspective on 280E ReliefIn the grand scheme, rescheduling cannabis represents a paradigm shift, fostering a more favorable regulatory environment. However, it’s vital for those in the cannabis industry—cultivators, dispensary owners, and industry stakeholders—to maintain cautious optimism about immediate financial relief. The journey toward tax equity is ongoing, and with long-term strategies and expert guidance, cannabis businesses can navigate the current tax hurdles while paving the way for a more equitable future.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*